Table 1 Characteristics of included studies
Study | Country or area | Design | Stage (% of patients) | no. of patients | Median age (years) | Adjuvant therapy (n) | Adjuvant regimen | Histology (% of patients) | Median follow-up (months) | Type of primary surgery (% of patients) | Quality assessmenta |
|---|---|---|---|---|---|---|---|---|---|---|---|
McEachron 2021 [14] | USA | R | IIIC (100%) | 144 | NR | AC (40) | TP; PTC; other | E (17%) | 66 | TH/BSO + pelvic/para aortic lymph node dissection (100%) | 7 |
ACR (104) | EBRT ± VBT | NE: SC (37%); CS (42%); CCA (4%) | |||||||||
Montes de Oca 2021 [17] | USA | R | IIIA (100%) | 671 | 58.3 | AC (286) | NR | E (100%) | NR | TH/BSO only (22.7%) | 6 |
ACR (385) | EBRT, VBT | TH/BSO + pelvic/para aortic lymph node dissection (77.3%) | |||||||||
Bogani 2020 [27] | USA | R | IIIC (100%) | 80 | NR | AC (24) | TC; TP; ACP; CP; PTC | E (48%) | NR | TH/BSO + pelvic/para aortic lymph node dissection (100%) | 7 |
ACR (56) | EBRT | NE (52%) | |||||||||
Huang 2020 [31] | Taiwan | R | IIIA (32%), IIIB (6%), IIIC (62%) | 125 | 57 | AC (67) | TP; TC; AP | E: 84% | 44 | TH/BSO + pelvic lymph node dissection (100%) | 8 |
ACR (58) | EBRT, VBT | NE: 16% | |||||||||
Ko 2020 [28] | USA | R | IIIA (41%), IIIB (17%), IIIC (42%) | 1301 | 73 | AC (779) | TP | E (63%) | 43.2 | TH/BSO only (9.2%) | 7 |
ACR (522) | EBRT, VBT | NE: SC (21%); CCA (4%); CS (12%) | TH/BSO + pelvic/para aortic lymph node dissection (80.8%) | ||||||||
Lee 2020 [32] | Taiwan | R | IIIC (100%) | 441 | 55 | AC (142) | NR | E (82%) | 43.2 | TH/BSO + pelvic/para aortic lymph node dissection (100%) | 7 |
57 | ACR (299) | EBRT | NE (18%) | ||||||||
van Weelden 2020 [25] | Netherlands | R | IIIA (30%), IIIB (8%), IIIC (62%) | 333 | 65.8 | AC (158) | NR | E (36%) | NR | TH/BSO only (25.5%) | 6 |
62.9 | ACR (175) | EBRT | NE: SC (40%); CCA (5%); CS (19%) | TH/BSO + pelvic/para aortic lymph node dissection (74.5%) | |||||||
Verrengia 2020 [34] | Italy | R | IIIA (28%), IIIB (9%), IIIC (63%) | 32 | NR | AC (14) | TP | E (72%) | 31 | TH/BSO + pelvic/para aortic lymph node dissection (100%) | 6 |
ACR (18) | EBRT, VBT | NE (28%) | |||||||||
Kahramanoglu 2019 [16] | Central Asia/Eastern Europe | R | IIIA (32%), IIIB (2%), IIIC (66%) | 787 | NR | AC (242) | TC | E (100%) | 42 | TH/BSO only (15.6%) | 6 |
ACR (545) | EBRT ± VBT | TH/BSO + pelvic/para aortic lymph node dissection (84.4%) | |||||||||
Kidd 2019 [15] | USA | R | IIIA (23%), IIIB (5%), IIIC (72%) | 13,072 | 60 | AC (7847) | NR | E (100%) | 44.4 | TH/BSO only (24.8%) | 7 |
60 | ACR (5225) | EBRT | TH/BSO + pelvic/para aortic lymph node dissection (75.2%) | ||||||||
Matei 2019 [12] | USA | RCT | IIIA (21%), IIIB (3%), IIIC (73%), IVA (1%) | 736 | 60 | AC (366) | TP | E (70%) | 47 | TH/BSO + pelvic and paraaortic lymph node biopsy or dissection (100%) | 5 |
ACR (370) | EBRT | NE: SC (18%); CCA (3%); other (9%) | |||||||||
Albuquerque 2018 [24] | USA | R | IIIA (39%), IIIB (8%), IIIC (53%) | 181 | 62 | AC (57) | TP; ACP; PTC | E (66%) | 31.5 | TH/BSO + pelvic/para aortic lymph node dissection (100%) | 5 |
ACR (124) | EBRT; VBT | NE (34%) | |||||||||
Binder 2017 [35] | USA | R | IIIC (100%) | 146 | 67.5 | AC (46) | TP; AP | E (73%) | 40.1 | TH/BSO + pelvic/para aortic lymph node dissection (100%) | 8 |
60.5 | ACR (100) | EBRT, IMRT, VBT | NE: CCA(14%); other (23%) | ||||||||
Signorelli 2015 [26] | Italy | R | IIIA (45%), IIIB (7%), IIIC (48%) | 75 | 61 | AC (46) | ACP; PAC; CP; CT; other | E/NE (NR) | 101 | TH/BSO only (23%) | 6 |
ACR (29) | EBRT | TH/BSO + pelvic/para aortic lymph node dissection (77%) | |||||||||
Kuku 2013 [29] | UK | R | IIIA (60%), IIIB (10%), IIIC (30%) | 58 | 67 | AC (7) | TP | E (65%) | 58 | TH/BSO only (70%) | 7 |
ACR (51) | EBRT ± VBT | NE: PSC (16%); CCA (4.3%); MCC (5.3%); other (9.4%) | TH/BSO + selective pelvic and/ or para-aortic lymph node dissection (30%) | ||||||||
Secord 2013 [30] | USA | R | IIIC (100%) | 207 | 61 | AC (46) | TP; ACP; PTC; CT; other | E (66%) | 42 | TH/BSO + selective or systematic lymphadenectomy (pelvic or pelvic and/or aortic) (100%) | 6 |
60 | ACR (161) | WPRT; WAR; VBT | NE: PSC (11%); MCC (18%); other (5%) |